![](/img/cover-not-exists.png)
Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Glassberg, Marilyn K., Nathan, Steven D., Lin, Chin-Yu, Morgenthien, Elizabeth A., Stauffer, John L., Chou, Willis, Noble, Paul W.Language:
english
Journal:
Advances in Therapy
DOI:
10.1007/s12325-019-01052-y
Date:
August, 2019
File:
PDF, 531 KB
english, 2019